author-photo

Bart A. Nijmeijer

Leiden University Medical Center

40

Papers

616

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

Enhanced Factor IX Activity Following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 wildtype Human Factor IX in Non-human Primates

2019 Molecular therapy. Methods & clinical development
Show All
- Source
- Cite
- Save
Citations (10)
Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors

2017 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (12)
Predictable Protein Expression with Enhanced Factor IX Activity Following Administration of a Modified AAV5-hFIX Vector to Nonhuman Primates

2017 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1-2 Clinical Trial of a Recombinant AAV5 Vector Containing the Human FIX Gene in Patients with Severe or Moderately Severe Haemophilia B

2014 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Donor T Cells Administered Over HLA Class II Barriers Mediate Antitumor Immunity without Broad Off-Target Toxicity in a NOD/Scid Mouse Model of Acute Leukemia

2013 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (5)
Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia

2013 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (49)
Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model

2012 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (51)
IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors.

2011 Blood
Show All
- Source
- Cite
- Save
Citations (36)
Leukemic CD52 Negative Subclones Due to Defective Glycophosphatidyl-Innositol Anchoring Are Common in Acute Precursor B Lymphoblastic Leukemia, Escape Alemtuzumab Therapy, but Display Increased Sensitivity to Rituximab Mediated Complement Dependent Cytotoxicity: a Mechanistic Rationale for Antibody Combination Therapy.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Long–term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors

2009 Experimental Hematology
Show All
- Source
- Cite
- Save
Citations (47)